Findings of Research Misconduct, 23599-23600 [2011-10150]

Download as PDF Federal Register / Vol. 76, No. 81 / Wednesday, April 27, 2011 / Notices Officer: Tarun Tandon, President (Qualifying Individual), Application Type: Add OFF Service. Worldwide Freight Logistics, Corp. (OFF), 9222 NW. 101 Street, Medley, FL 33178, Officers: Heriberto Sanchez, Secretary/Treasurer (Qualifying Individual), Roxana Sanchez, CEO, Application Type: New OFF License. Dated: April 22, 2011. Karen V. Gregory, Secretary. [FR Doc. 2011–10160 Filed 4–26–11; 8:45 am] BILLING CODE 6730–01–P FEDERAL RESERVE SYSTEM Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than May 12, 2011. A. Federal Reserve Bank of Minneapolis (Jacqueline G. King, Community Affairs Officer) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291: 1. James Anton Senty, Onalaska, Wisconsin, to acquire control of Northern Financial Corporation, and thereby indirectly acquire control of Independence State Bank, both of Independence, Wisconsin. Board of Governors of the Federal Reserve System, April 22, 2011. Robert deV. Frierson, Deputy Secretary of the Board. WReier-Aviles on DSKGBLS3C1PROD with NOTICES [FR Doc. 2011–10134 Filed 4–26–11; 8:45 am] pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 20, 2011. A. Federal Reserve Bank of St. Louis (Glenda Wilson, Community Affairs Officer) P.O. Box 442, St. Louis, Missouri 63166–2034: 1. Canton Bancshares, Inc., Hannibal, Missouri, to acquire 100 percent of the voting shares of Canton State Bank, Canton, Missouri. Board of Governors of the Federal Reserve System, April 22, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–10133 Filed 4–26–11; 8:45 am] BILLING CODE 6210–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct ACTION: BILLING CODE 6210–01–P Office of the Secretary, HHS. Notice. AGENCY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Vipul Bhrigu, PhD, University of Michigan Medical School: Based on the findings of an investigation by the University of Michigan Medical School SUMMARY: FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, VerDate Mar<15>2010 15:36 Apr 26, 2011 Jkt 223001 PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 23599 (UMMS) and additional analysis conducted by the Office of Research Integrity (ORI) during its oversight review, ORI found that Vipul Bhrigu, PhD, former postdoctoral fellow, Department of Internal Medicine, UMMS, engaged in research misconduct in research funded by National Cancer Institute (NCI), National Institutes of Health (NIH), grant R01 CA098730–05. Specifically, ORI found that the Respondent knowingly and intentionally tampered with research materials related to five (5) immunoprecipitation/Western blot experiments and switched the labels on four (4) cell culture dishes for cells used in the same type of experiments to cause false results to be reported in the research record. ORI also found that the Respondent tampered with laboratory research materials by adding ethanol to his colleague’s cell culture media, with the deliberate intent to effectuate the death of growing cells, which caused false results to be reported in the research record. ORI has concluded that these acts seriously deviated from those that are commonly accepted within the scientific community for proposing, conducting, and/or reporting research. ORI found that the Respondent’s intentional tampering of his colleague’s laboratory research constitutes research misconduct as defined by 42 CFR part 93. ORI determined that the Respondent engaged in a pattern of dishonest conduct through the commission of multiple acts of data falsification. ORI also determined that the subterfuge in which he freely engaged for several months constitutes an aggravating factor. The Respondent attempted to mislead the University of Michigan (UM) police by initially denying involvement in the tampering and refusing to accept responsibility for this misconduct. The Respondent eventually made an admission only after the UM police informed him that his actions in the laboratory had been videotaped. This dishonest conduct established the Respondent’s lack of present responsibility to be a steward of Federal funds (2 CFR 376 et seq.; 42 CFR 93.408). The following administrative actions have been implemented for a period of three (3) years, beginning on April 7, 2011: (1) Dr. Bhrigu is debarred from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement programs of the United States Government, referred to as ‘‘covered transactions,’’ pursuant to HHS’ Implementation of OMB E:\FR\FM\27APN1.SGM 27APN1 23600 Federal Register / Vol. 76, No. 81 / Wednesday, April 27, 2011 / Notices Guidelines to Agencies on Governmentwide Debarment and Suspension (2 CFR 376 et seq.); and (2) Dr. Bhrigu is prohibited from serving in any advisory capacity to the U.S. Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2011–10150 Filed 4–26–11; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. ACTION: Notice. AGENCY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Junghee J. Shin, PhD, New York Medical College: Based on the report of an investigation conducted by New York Medical College (NYMC) and additional analysis by the Office of Research Integrity (ORI) in its oversight review, the U.S. Public Health Service (PHS) found that Junghee J. Shin, PhD, former graduate student, NYMC, engaged in research misconduct in research supported by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grants R01 AI048856 and R01 AI043063. PHS found that the Respondent engaged in research misconduct by falsifying data in Figure 4 of a manuscript submitted to the journal Infection and Immunity (Shin, J.J., Godfrey, H.P., & Cabello, F.C. ‘‘Expression and localization of BmpC in Borrelia burgdorferi after growth under various environmental conditions.’’ Submitted to Infection and Immunity; hereafter referred to as the ‘‘manuscript’’) and Figure 5 of a paper published in Infection and Immunity (Shin, J.J. Bryksin, A.V., Godfrey, H.P., & Cabello, F.C. ‘‘Localization of BmpA on the exposed outer membrane of Borrelia burgdorferi by monospecific anti-recombinant BmpA rabbit WReier-Aviles on DSKGBLS3C1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 15:36 Apr 26, 2011 Jkt 223001 antibodies.’’ Infection and Immunity 72(4):2280–2287, April 2004; hereafter referred to as the ‘‘paper.’’ Retracted in: Infection and Immunity 76(10):4792, October 2008). Specifically, NYMC and ORI found that: • Dr. Shin falsified microscopic immunofluorescence blank images in Figure 4 of the manuscript (top row, 1st, 2nd, 4th, and 5th panels, and bottom row, 1st panel) and Figure 5 of the paper (top row, 1st and 5th panels, lower 1st panel) by using one blank image from an unknown experiment to falsely represent the preimmunization control conditions (intact cells and methanol fixation) as well as the negative staining of anti-BmpC and anti-FlaB in Figure 4 and anti-FlaB in Figure 5 on intact cells. • Dr. Shin falsified at least one of two images in Figure 4 of the manuscript and Figure 5 of the paper by using different portions of a green-red pair of microscopic immunofluorescence images (1230036.tif and 1230037.tif) because unfixed cells staining positive for BmpA in the top row, 4th panel, of Figure 5 were the same unfixed cells purportedly positive for OspA in the top row, 3rd panel, of Figure 4. • Dr. Shin falsified at least one of two images in Figure 4 of the manuscript and Figure 5 of the paper by using different photo cropping from a single microscopic immunofluorescence image (1230039.tif) to represent fixed cells positive for BmpA and labeled with anti-FlaB in the lower row, 5th panel, of Figure 5 and to also represent fixed cells positive for BmpC and stained with anti-FlaB in the lower row, 5th panel, of Figure 4. Dr. Shin has entered into a Voluntary Settlement Agreement in which she has voluntarily agreed, for a period of three (3) years, beginning on April 5, 2011: (1) That any institution that submits an application for PHS support for a research project on which the Respondent’s participation is proposed or that uses her in any capacity on PHSsupported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to ORI for approval; the supervisory plan must be designed to ensure the scientific integrity of her research contribution; Respondent agrees that she will not participate in any PHS-supported research until such a supervision plan is submitted to ORI; and (2) to exclude herself voluntarily from service in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2011–10157 Filed 4–26–11; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry [CDC–2011–0005] Availability of Draft Toxicological Profile Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (DHHS). ACTION: Notice of availability. AGENCY: This notice announces the availability of the Toxicological Profile for Uranium (Update) for review and comment. These comments can include additional information or reports on studies about the health effects of uranium. Although ATSDR considered key studies for uranium during the profile development process, this Federal Register notice solicits any relevant, additional studies, particularly unpublished data. ATSDR will evaluate the quality and relevance of such data or studies for possible addition to the profile. ATSDR remains committed to providing a public comment period for this document as a means to best serve public health and our clients. The Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), as amended by the Superfund Amendments and Reauthorization Act of 1986 (SARA), § 104(i)(3), [42 U.S.C. 9604(i)(3)], directs the ATSDR administrator to prepare toxicological profiles of priority hazardous substances and, as necessary, to revise and publish each updated toxicological profile. DATES: To be considered, comments on this draft toxicological profile must be received not later than July 29th, 2011. Comments received after the close of the public comment period will be considered at the discretion of ATSDR, based upon what is deemed to be in the best interest of the general public. ADDRESSES: Requests for printed copies of the draft toxicological profile should be sent via e-mail to cdcinfo@cdc.gov, or SUMMARY: E:\FR\FM\27APN1.SGM 27APN1

Agencies

[Federal Register Volume 76, Number 81 (Wednesday, April 27, 2011)]
[Notices]
[Pages 23599-23600]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10150]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Vipul Bhrigu, PhD, University of Michigan Medical School: Based on 
the findings of an investigation by the University of Michigan Medical 
School (UMMS) and additional analysis conducted by the Office of 
Research Integrity (ORI) during its oversight review, ORI found that 
Vipul Bhrigu, PhD, former postdoctoral fellow, Department of Internal 
Medicine, UMMS, engaged in research misconduct in research funded by 
National Cancer Institute (NCI), National Institutes of Health (NIH), 
grant R01 CA098730-05.
    Specifically, ORI found that the Respondent knowingly and 
intentionally tampered with research materials related to five (5) 
immunoprecipitation/Western blot experiments and switched the labels on 
four (4) cell culture dishes for cells used in the same type of 
experiments to cause false results to be reported in the research 
record. ORI also found that the Respondent tampered with laboratory 
research materials by adding ethanol to his colleague's cell culture 
media, with the deliberate intent to effectuate the death of growing 
cells, which caused false results to be reported in the research 
record. ORI has concluded that these acts seriously deviated from those 
that are commonly accepted within the scientific community for 
proposing, conducting, and/or reporting research.
    ORI found that the Respondent's intentional tampering of his 
colleague's laboratory research constitutes research misconduct as 
defined by 42 CFR part 93. ORI determined that the Respondent engaged 
in a pattern of dishonest conduct through the commission of multiple 
acts of data falsification. ORI also determined that the subterfuge in 
which he freely engaged for several months constitutes an aggravating 
factor. The Respondent attempted to mislead the University of Michigan 
(UM) police by initially denying involvement in the tampering and 
refusing to accept responsibility for this misconduct. The Respondent 
eventually made an admission only after the UM police informed him that 
his actions in the laboratory had been videotaped. This dishonest 
conduct established the Respondent's lack of present responsibility to 
be a steward of Federal funds (2 CFR 376 et seq.; 42 CFR 93.408).
    The following administrative actions have been implemented for a 
period of three (3) years, beginning on April 7, 2011:
    (1) Dr. Bhrigu is debarred from eligibility for any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility for, or involvement in, nonprocurement programs of the 
United States Government, referred to as ``covered transactions,'' 
pursuant to HHS' Implementation of OMB

[[Page 23600]]

Guidelines to Agencies on Governmentwide Debarment and Suspension (2 
CFR 376 et seq.); and
    (2) Dr. Bhrigu is prohibited from serving in any advisory capacity 
to the U.S. Public Health Service (PHS), including but not limited to 
service on any PHS advisory committee, board, and/or peer review 
committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2011-10150 Filed 4-26-11; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.